TF-LNPS-Based Delivery of Emodin Alleviates Hippocampal Neuronal PANoptosis in Diabetic Encephalopathy Rats via the HDAC4/NF-κB Pathway

Technical Summary: TF-LNPS-Based Delivery of Emodin for Diabetic Encephalopathy

Problem Statement
Diabetic encephalopathy (DE) is a severe complication of diabetes characterized by cognitive decline, learning and memory deficits, and neuronal damage. Current treatments primarily focus on glycemic control (e.g., insulin, metformin) but lack specific efficacy against the neurodegenerative changes and cognitive dysfunction associated with DE. Furthermore, the therapeutic potential of traditional Chinese medicine (TCM) components, such as emodin (a major active ingredient of Polygonum multiflorum), is limited by poor water solubility, low bioavailability, rapid metabolism, and an inability to effectively cross the blood-brain barrier (BBB). Additionally, the specific mechanism of "PANoptosis"—a unified form of inflammatory programmed cell death involving apoptosis, pyroptosis, and necroptosis—in the context of DE remains unexplored.

Methodology
The study employed a multi-faceted approach combining in vivo animal models, in vitro cell cultures, and advanced nanotechnology:

• Animal Models: A Type 1 Diabetes Mellitus (T1DM) rat model was induced using Streptozotocin (STZ). Rats were treated with emodin via gavage.
• Cell Models: HT-22 hippocampal neurons and hCMEC/D3 human brain microvascular endothelial cells were used to simulate high-glucose damage and the BBB, respectively.
• Nanocarrier Development: Transferrin (TF)-modified liposomal nanoparticles (TF-LNPs) were engineered to encapsulate emodin. The TF modification was intended to leverage receptor-mediated endocytosis to cross the BBB.
• Mechanistic Investigation:
  • Network Pharmacology & Molecular Docking: Used to predict emodin targets, specifically focusing on Histone Deacetylase 4 (HDAC4).
  • Binding Verification: Surface Plasmon Resonance (SPR) and molecular docking were used to confirm the direct binding between emodin and HDAC4.
  • Pathway Analysis: Western blot, immunohistochemistry (IHC), immunofluorescence (IF), and ELISA were utilized to assess the HDAC4/NF-κB signaling axis and PANoptosis markers (ZBP1, Caspase-8, NLRP3, GSDMD, etc.).
• Evaluation: Behavioral tests (Morris Water Maze), histological staining (HE, Nissl), BBB permeability assays (Transwell), and in vivo imaging were conducted to evaluate therapeutic efficacy and delivery efficiency.

Key Contributions

1. Discovery of PANoptosis in DE: The study is the first to report the occurrence of PANoptosis in the hippocampal neurons of diabetic encephalopathy rats, identifying it as a critical mechanism for neuronal loss.
2. Mechanistic Elucidation: The research establishes that emodin alleviates neuronal PANoptosis by inhibiting the HDAC4/NF-κB signaling pathway. Specifically, emodin binds to HDAC4, reducing its activity and nuclear translocation, which subsequently suppresses the NF-κB pathway and downregulates PANoptosis-related proteins (e.g., ZBP1).
3. Novel Delivery System: The study introduces a TF-LNPs-Emodin delivery system. This nanocarrier addresses the pharmacokinetic limitations of free emodin, demonstrating enhanced stability, biocompatibility, and the ability to penetrate the BBB via transferrin receptor targeting.
4. Therapeutic Efficacy: The TF-LNPs-Emodin formulation was shown to significantly improve cognitive function and reduce hippocampal neuronal damage in diabetic rats more effectively than free emodin.

Results

• Cognitive Improvement: Emodin treatment significantly improved learning and memory capabilities in diabetic rats, as evidenced by reduced escape latency and increased platform crossings in the Morris Water Maze. Histological analysis confirmed reduced neuronal loss and improved arrangement in the hippocampal CA1 region.
• Inhibition of PANoptosis: In both animal and cell models, emodin treatment significantly reduced the expression of PANoptosis markers (ZBP1, Cleaved Caspase-8, GSDMD, etc.).
• HDAC4/NF-κB Axis: Emodin treatment decreased HDAC4 expression and activity. Nuclear-cytoplasmic separation experiments showed that emodin inhibited the nuclear translocation of both HDAC4 and NF-κB (p65). This inhibition correlated with a reduction in PANoptosis receptor ZBP1.
• Nanocarrier Performance:
  • Characterization: TF-LNPs-Emodin exhibited a particle size of 100–200 nm, a uniform spherical morphology, and high encapsulation efficiency.
  • Safety: The formulation showed low hemolysis rates (<1.5%) and no significant toxicity to major organs (heart, liver, kidneys) or hematological parameters in mice.
  • BBB Penetration: In vitro Transwell assays and in vivo imaging demonstrated that TF-LNPs-Emodin crossed the BBB more efficiently than free emodin or unmodified LNPs, leading to higher drug concentrations in the brain and hippocampus.
  • Therapeutic Outcome: The TF-LNPs-Emodin group showed superior reduction in PANoptosis markers compared to the free emodin group, confirming that the delivery system enhances the therapeutic effect.

Significance and Claims
The authors claim this study provides the first report of a TF-LNPs delivery system specifically designed for treating diabetic encephalopathy. The work highlights the following significance:

• Theoretical Basis: It offers a new theoretical framework for understanding DE pathogenesis by linking HDAC4 overexpression to neuronal PANoptosis via the NF-κB pathway.
• TCM Modernization: It demonstrates a strategy for modernizing TCM by isolating active components (emodin), elucidating their molecular mechanisms, and overcoming delivery barriers through nanotechnology.
• Clinical Potential: The TF-LNPs-Emodin system presents a promising, safe, and effective strategy for treating DE, potentially serving as a template for developing targeted therapies for other neurodegenerative diseases involving BBB penetration challenges.
• Future Directions: The authors note that while TF-LNPs showed broad brain distribution, future work will focus on optimizing the system for more precise hippocampal targeting and exploring its potential for liver-targeted therapies, given the observed hepatic aggregation.